Because the absence of significant additive effects was observed by combining I-BET762 and PARP inhibitors in the two MAX-deleted SCLC cell lines, Lu134 and Lu165, our results indicate that these investigational drugs have a preferential or selective combinatorial efficacy on SCLC cells with an active MYC signaling pathway. The gene discussed is PARP1; the disease is small cell lung carcinoma.